This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Lithuania, Poland, UK.
The drug CUFENCE contains one active pharmaceutical ingredient (API):
1
|
UNII
HC3NX54582 - TRIENTINE HYDROCHLORIDE
|
|
Trientine is a copper-chelating agent whose principal mechanism of action is to eliminate absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine may also chelate copper in the intestinal tract and so inhibit copper absorption. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A16AX12 | A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EE | Ravimiamet | 1800021 |
| FR | Base de données publique des médicaments | 65919229 |
| GB | Medicines & Healthcare Products Regulatory Agency | 390459 |
| IE | Health Products Regulatory Authority | 89011 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1088312 |
| PL | Rejestru Produktów Leczniczych | 100427110 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.